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Pathologically increased vascular permeability is an important dysfunction in the
pathomechanism of life-threatening conditions, such as sepsis, ischemia/reperfusion,
or hereditary angioedema (HAE), diseases accompanied by uncontrolled activation of
the complement system. HAE for example is caused by the deficiency of C1-inhibitor
(the main regulator of early complement activation), which leads to edematous attacks
threatening with circulatory collapse. We have previously reported that endothelial cells
become activated during HAE attacks. A natural target of C1-inhibitor is mannan-binding
lectin-associated serine protease-1 (MASP-1), a multifunctional serine protease, which
plays a key role in the activation of complement lectin pathway. We have previously
shown that MASP-1 induces the pro-inflammatory activation of endothelial cells
and in this study we investigated whether MASP-1 can directly affect endothelial
permeability. All experiments were performed on human umbilical vein endothelial
cells (HUVECs). Real-time micro electric sensing revealed that MASP-1 decreases
the impedance of HUVEC monolayers and in a recently developed permeability
test (XperT), MASP-1 dose-dependently increased endothelial paracellular transport.
We show that protease activated receptor-1 mediated intracellular Ca2+-mobilization,
Rho-kinase activation dependent myosin light chain (MLC) phosphorylation, cytoskeletal
actin rearrangement, and disruption of interendothelial junctions are underlying this
phenomenon. Furthermore, in a whole-transcriptome microarray analysis MASP-1
significantly changed the expression of 25 permeability-related genes in HUVECs—for
example it up-regulated bradykinin B2 receptor expression. According to our results,
MASP-1 has potent permeability increasing effects. During infections or injuries MASP-1
may help eliminate the microbes and/or tissue debris by enhancing the extravasation
of soluble and cellular components of the immune system, however, it may also play a
role in the pathomechanism of diseases, where edema formation and complement lectin
pathway activation are simultaneously present. Our findings also raise the possibility that
MASP-1 may be a promising target of anti-edema drug development.
Keywords: MASP-1, endothelial cell, permeability, PAR-1, angioedema, C1-inhibitor, XPerT assay, transcriptome
analysis
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INTRODUCTION
Mannan-binding lectin-associated serine protease-1 (MASP-1)
is a multifunctional serine protease of complement and
coagulation. MASP-1 is indispensable for the activation of the
complement lectin pathway, circulating in a zymogen form in
complex with pattern recognition molecules (PRMs) mannan
binding lectin (MBL), ficolins or collectins, serin proteases
MASP-2 and MASP-3, and non-catalytic proteins MAp19/MAP-
2 and Map44/MAP-1 (1, 2). The most well-known function of
MASP-1 is its central, zymogen MASP-activating role during
lectin pathway activation (3, 4). According to the latest model,
MASP-1 auto-activates upon the binding of the PRM to an
activator surface, then activates zymogen MASP-2, which then
cleaves C4, and both MASP-1 and MASP-2 cleave C2 to form
C3 convertase C4bC2a (2). Although, being a promiscuous
protease with a relatively large and open substrate-binding cleft
(5), MASP-1 is capable of cleaving a great variety of substrates
in- and outside the complement system. It can activate MASP-
3 and possibly contribute to alternative pathway activation (4,
6). Furthermore, it cleaves fibrinogen, Factor XIII, thrombin
activatable fibrinolysis inhibitor (TAFI) and prothrombin to
promote blood clotting and coagulation (7–10). MASP-1 is also
able to deliberate the potent edematogenic agent bradykinin from
high molecular weight kininogen (HMWK) (11). Moreover, as
we have shown previously, it can activate endothelial cells (ECs)
(12, 13), triggering the production of interleukins IL-6 and IL-8
(14) and up-regulating endothelial E-selectin expression (15).
Activity ofMASP-1 is controlled from both in- and outside the
initiation complex. An intracomplex inhibitor ofMASP activity is
the above mentionedMAP-1 that was found to be able to displace
all three MASPs on MBL. In mouse models, administration
of MAP-1 successfully preserved cardiac function, decreased
infarct size and C3 deposition, inhibited MBL deposition and
prevented thrombogenesis (1). Serine protease activity of MASP-
1, however, is controlled mainly by C1-inhibitor (C1-INH),
a circulating serine protease inhibitor, which is the most
important regulator of early complement activation and several
other plasma enzyme systems. Genetic deficiency of C1-INH
causes hereditary angioedema (HAE), a rare, life-threatening
disease characterized by vascular hyperpermeability leading to
edematous attacks (16, 17). We have also shown that during these
attacks, ECs become activated (18).
Since C1-INH is not specific for MASP-1, we have developed a
highly specific, artificial MASP-1 inhibitor, SGMI-1 (Schistocerca
gregaria protease inhibitor-based MASP-1 inhibitor) to study the
physiological and pathophysiological roles of MASP-1 (19).
ECs have numerous physiological roles; besides regulating
blood-pressure, hemostasis, leukocyte homing, and several
other processes, they control vascular permeability, which can
take place via both paracellular and transcellular routes. The
well-known permeability inducing agonists—such as thrombin,
histamine, or bradykinin—increase the intensity of paracellular
transport by disrupting endothelial cell-cell adhesion (20, 21).
Thrombin exerts its cellular effects by cleaving protease
activated receptors (PARs) on the surface of ECs. These receptors
are members of the G-protein coupled receptor family. PARs
have an N-terminal region sensitive to proteolytic cleavage,
and specific limited proteolysis within this segment unmasks a
tethered, self-activating ligand on the receptor. This protease-
induced receptor activation elicits a rise in intracellular [Ca2+],
and through a complex signaling mechanism involving myosin
light chain kinase (MLCK) and Rho-kinase (ROCK) activation
leads to myosin light chain (MLC) di-phosphorylation, actin
stress fiber formation, cell contraction, redistribution of
junctional adhesion- and adapter molecules—for example
vascular endothelial cadherin (VE-cadherin) and zonula
occludens-1 (ZO-1)—and finally, dissociation of endothelial
cell-cell junctions (22). MASP-1 and thrombin share several
structural and functional similarities (5) and we have previously
reported that similarly to thrombin, MASP-1 can also activate
ECs by cleaving cell surface PARs (12, 13). It is also known that
in the pathomechanism of HAE, deficiency of C1-INH—the
natural inhibitor of MASP-1—leads to edema formation due
to increased vascular permeability. Furthermore, in certain
cases—such as bacterial/fungal infection, tissue necrosis, or
inflammation triggered HAE attacks—lectin pathway was found
to be activated during attacks (23). These observations led
us to ask the question, whether MASP-1 can directly affect
endothelial permeability.
Here we show that the recombinant catalytic fragment of
MASP-1 (rMASP-1), which is enzymatically equivalent with
full-length plasma purified MASP-1, significantly and dose-
dependently increases endothelial permeability in a PAR-1 and
ROCK dependent manner. Furthermore, we demonstrate that
rMASP-1 affects the expression of permeability-related genes in
human umbilical vein ECs (HUVECs) as well.
MATERIALS AND METHODS
Reagents
rMASP-1 was produced in Escherichia coli (24) and purified by
the method described by Dobó et al. (25). Purity of rMASP-
1 preparations was checked as described earlier (13, 15) and
found to be free of bacterial contaminations. Furthermore, C1-
INH completely inhibited all tested effects of rMASP-1, and the
enzymatically inactive mutant (S646A) as well as the zymogen
mutant (R448Q) variants of rMASP-1 (produced in the same
expression system (4) did not elicit any cellular response.
The highly selective MASP-1 inhibitor SGMI-1 used in our
experiments was produced according to the method described
earlier by Héja et al. (19), and was found to be non-toxic to ECs.
Other reagents were purchased from Sigma-Aldrich, unless
stated otherwise.
Preparation and Culturing of HUVECs
ECs were harvested by collagenase digestion from fresh umbilical
cords obtained during normal deliveries of healthy neonates as
described earlier (14, 26). HUVECs were cultured in gelatin
pre-coated flasks (Corning R© Costar R©) in AIM-V medium (Life
Technologies) completed with 1% filtrated, heat inactivated
bovine serum (PAN Biotech), 1 ng/mL human recombinant basic
fibroblast growth factor, 2 ng/mL human recombinant epidermal
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growth factor (R&D Systems), and 7.5 U/mL heparin; hereinafter
referred to as Comp-AIM-V.
Experiments were performed on HUVECs from at least
three different individuals, before passage 4. The study
was conducted in conformity with the WMA Declaration
of Helsinki; its protocol was approved by the Semmelweis
University Institutional Review Board (permission number:
TUKEB141/2015). All participants provided their written
informed consent before inclusion.
Real-Time Cell Microelectronic Sensing
Changes in the impedance of HUVEC monolayers were
measured using the xCELLingence system (Roche, Hungary) as
described earlier (27). Briefly, a 96-well E-plate (Roche, Hungary)
mounted by golden microelectronic sensor arrays was pre-coated
with 0.5% gelatin, and HUVECs were seeded onto the surface
and cultured for 3 days. Confluent HUVEC monolayers were
treated with (i) 2µM rMASP-1; or (ii) 100 nM thrombin or (iii)
culture medium. Throughout the experiments, cells were kept in
incubator at 37◦C andmonitored every 1min. Cell index for each
time point was determined using the following formula: (Rn—
Rb)/15, where Rn is the cell-electrode impedance of the well when
it contains cells and Rb is the background impedance of the well
with the medium alone.
Permeability Measurements
Permeability tests were carried out using a modified version of
the recently developed XPerT technique (28). Confluent layers
of HUVECs were seeded onto 96-well plates pre-coated with
250µg/ml biotinylated gelatin, and were cultured in Comp-
AIMV medium for 2 days. After cell treatment, Streptavidin-
Alexa488 (2µg/ml, Life Technologies) was added to each well
for 2min. Cells were fixed with 1% paraformaldehyde-PBS and
2 pictures of each well were taken using an Olympus IX-81
fluorescence microscope and an Olympus XM-10 camera. Size of
the stained area was determined on each image by quantitative
image analysis using the CellP software (Olympus). Thrombin
(300 nM, Merck Millipore) was used as a positive control in
every test.
Dose dependence of rMASP-1 treatment was examined using
0.2, 0.6, or 2µMof rMASP-1. In other experiments rMASP-1 was
used at 2µM. Inhibitors of rMASP-1, 6µM of human plasma
derived C1-INH (Berinert R©, CSL Behring) or 20µM of SGMI-
1 were pre-incubated with rMASP-1 at room temperature for
30min before treating HUVECs. In experiments investigating
the PAR-dependence of the rMASP-1 triggered permeability, cells
were either treated with one of the following PAR antagonists,
PAR-1: RWJ 56110; PAR-2: FSLLRY-NH2; PAR-4: ML 354 for
5min, or with the culture medium alone, and then were treated
either with rMASP-1 or one of the following PAR agonists, PAR-
1: TFLLR-NH2; PAR-2: AC 55541; PAR-4: AY-NH2 for 20 min—
for the concentrations used, see Figure 3. All antagonists and
agonists were purchased from Tocris Bioscience. Effects of the
inhibition of protein kinases MLCK and ROCK on rMASP-1
induced permeability was tested by pretreating the cells with
inhibitorsML-7 (MLCK inhibitor, 10µM, Tocris Bioscience) and
Y-27632 (ROCK inhibitor, 2.5µM, Tocris Bioscience) for 15min
before rMASP-1 treatment. Minimum doses of PAR-agonists/-
antagonists and protein kinase inhibitorsML-7 and Y-27632 were
determined according to the literature data.
Intracellular Ca2+ Mobilization Assay
Intracellular Ca2+ mobilization has been measured as described
earlier (12). Confluent layers of HUVECs were seeded onto 96-
well plates and cultured in Comp-AIM-V for 1 day. Cells were
loaded with 2µM Fluo-4-AM (Molecular Probes) for 20min,
then incubated in HBSS for another 20min. Cells were treated
with or without PAR antagonists for 5min, then sequential
images were obtained every 5 s by fluorescence microscopy.
Three photos were taken to determine the baseline fluorescence,
then cells were treated with 2µM rMASP-1 or PAR-agonists
and the response was measured for 2min. (For PAR-agonist
and—antagonist concentrations, see Figure 4.)
Twenty cells per image were then analyzed using the
CellP software.
MLC Phosphorylation and Cytoskeletal
Actin Visualization
Confluent layers of HUVECs were seeded onto 18-well ibidi
TM
slides and cultured in Comp-AIMV medium for 2 days.
Cells were pretreated with or without PAR-antagonists for
5min, then were treated either with 2µM rMASP-1 or with
300 nM thrombin for 20min. In other experiments, cells
were pretreated with 10µM ML-7 or 2.5µM Y-27632 or
culture medium only for 15min. After 1% paraformaldehyde-
PBS fixation, cells were stained with anti-diphospho MLC
(pMLC) antibody (Cell Signaling). F-actin cytoskeleton was
stained with phalloidin-Alexa488. Cell nuclei were labeled
with Hoechst 33258 (Thermo Fisher, 200 ng/mL). Pictures
were taken using a fluorescence microscope and camera
described above. For the calculation of co-localization (Pearson’s
R value), we used ImageJ 1.52i software, Coloc2 analysis
(Costes threshold regression) on background subtracted,
deconvoluted pictures.
Visualization of Adhesion Molecules
Confluent layers of HUVECs were seeded onto 18-well ibidiTM
slides and cultured for 2 days. Cells were treated with (i)
300 nM thrombin; or (ii) 2µM rMASP-1; or (iii) a mixture of
2µM rMASP-1 and 6 µMC1-INH; or (iv) culture medium for
20min. After fixation, cells were stained with anti-VE-cadherin
(Santa Cruz) anti-ZO-1 (Invitrogen) or anti-platelet-endothelial
cell adhesion molecule-1 (PECAM-1) (Bender MedSystems)
antibodies, followed by Alexa-488 labeled secondary antibodies.
Cell nuclei were labeled with Hoechst 33258. Images were taken
using fluorescence microscopy.
Whole Transcriptome Microarray Analysis
Total RNA isolation and microarray processing were carried
out as described in our earlier study (29). Briefly, confluent
layers of HUVECs from four individuals were cultured in
6-well plates and treated for 2 h with 0.6µM rMASP-1. To
compare the effects of rMASP-1 with other EC activators, cells
were treated with one of the following compounds: 300 nM
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TABLE 1 | rMASP-1 significantly changes the expression of permeability related genes.
Median of fold change by
rMASP-1
Gene
symbol
Gene name by HUGO
Gene Nomenclature
Committee (HGNC)
Description of the permeability
related function
Other activators
LPS Histamine Thrombin TNF-α
UP-REGULATED
4.09 F3 Coagulation factor III, tissue
factor
Important mediator of the endothelial
hyperpermeability induced by TNF-α,
which exerts its permeability
increasing effect by the up-regulation
of endothelial cell surface tissue factor
(30)
↑ ↑ ↑ ↑
3.38 FZD7 Frizzled class receptor 7 Adherent junction (AJ) protein which
co-localizes with VE-cadherin and has
an important role in the stabilization of
the endothelial barrier (31)
3.35 RCAN1 Regulator of calcineurin 1 Synthetized in response to histamine
treatment, and has a role in reducing
endothelial barrier breakdown (32)
↑ ↑ ↑ ↑
2.78 GHSR Growth hormone
secretagogue receptor
Mediates the effect of ghrelin.
Reduces the permeability increasing
effect of LPS (33) and also prevents
the increase in the blood-brain barrier
permeability following traumatic brain
injury (34)
↑
2.54 FOXF1 Fork head box F1 Transcription factor important in the
maintenance of endothelial barrier
function (35)
↑ ↑ ↑ ↑
2.32 TLR2 Toll like receptor 2 Mediates post-ischemic permeability
increase (36)
↑
2.24 KITLG KIT ligand Binds to endothelial c-Kit receptor
and increases endothelial permeability
through the stimulation of
VE-cadherin internalization (37, 38)
↑ ↑
2.17 BDKRB2 Bradykinin receptor B2 Receptor for the well-known
edematogenic factor bradykinin. Also
an important pharmacological target
in HAE therapy (39)
↑ ↑
2.03 TGFBR1 Transforming growth factor
beta receptor 1
TGF-β induces endothelial cell
contraction and increases endothelial
permeability through this receptor
(40, 41)
↑ ↑ ↑
DOWN-REGULATED
−2.90 EDNRB Endothelin receptor type B Receptor for endothelin-1, which
reduces the permeability increasing
effect of bradykinin and ATP through
this receptor (42)
↓ ↓ ↓ ↓
−2.58 APLNR Apelin receptor Mediator of the effects of apelin,
which is important for the stabilization
of the endothelial barrier of both
blood and lymphatic vessels (43–45)
−2.30 CCR3 C-C motif chemokine
receptor 3
Eotaxin increases endothelial
permeability through this receptor (46)
↓
Confluent layers of HUVECs from four individuals were cultured in 6 well plates and treated for 2 h with 0.6µM rMASP-1. To compare the effects of rMASP-1 with other endothelial
cell (EC) activators, cells were treated with 300 nM thrombin, 10 ng/mL TNFα, 100 ng/mL LPS, or 50µM histamine. The table contains the median fold-change (FC) values of the 4
independent HUVECs. From the set of genes significantly changed by rMASP-1, possible permeability-related genes were filtered out using REACTOME, KEGG, and GO databases.
Experimental evidence for the permeability related function of these genes were verified according to the current literature. This table contains only those genes with a protein product
proven to play a role in endothelial permeability regulation supported by direct experimental evidence. Terms and pathways used to filter out possible permeability related genes from
databases: GO—permeability; junction; actin; adhesion; camp; cgmp; rho; calcium. REACTOME—Cell junction organization; Extracellular matrix organization; Cell surface interactions
at the vascular wall; Toll-like receptors cascades; Complement cascade; Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways. KEGG—Cell
adhesion molecules; Adherens junction; Focal adhesion; Tight junction; Gap junction; Complement and coagulation cascades; Toll-like receptor signaling pathway; NOD-like receptor
signaling pathway; RIG-I-like receptor signaling pathway; Leukocyte transendothelial migration. ↑: Gene expression was up-regulated by the given activator; ↓: Gene expression was
up-regulated by the given activator.
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thrombin, 10 ng/mL tumor necrosis factor-α (TNFα), 100 ng/mL
lipopolysaccharide (LPS), 50µM histamine. All microarray
data are available at the Gene Expression Omnibus database
at NCBI (series accession number GSE98114). Microarray
data were validated by quantitative polymerase chain reaction
for 19 genes, 3 of which—F3, TGFBR1 and EDNRB—were
permeability-related genes.
From the set of genes having expression levels significantly
altered by rMASP-1 treatment, genes without known connection
with permeability were excluded based on REACTOME, KEGG
and GO databases. Experimental evidence for the permeability
related function of the remaining list of genes was verified
according to the current literature. Genes that could be linked
to permeability regulation were divided into three groups based
on the type of evidence for their role in the modulation of
endothelial permeability: (i) direct evidence—protein products
of these genes have been directly proven to affect endothelial
permeability (ii) indirect evidence—protein products of these
genes have been proven to affect the function of known
permeability regulating factors, and (iii) potential role—protein
products of these genes are suspected to influence the barrier
properties of the endothelium. Genes in the (i) and (ii) categories
are also proven to be expressed in ECs at protein level.
Table 1 contains the median fold-change (FC) values of 4
independent HUVECs.
Statistical Analysis
Experiments were performed in triplicates and repeated at least
three times using HUVECs from different individuals. Statistical
analysis was done using the Prism 5.01 software (GraphPad).
One-way ANOVA with Tukey post test was conducted to
determine the statistical significance of the results. A p ≤ 0.05
was considered significant.
RESULTS
rMASP-1 Treatment Decreases the
Impedance of Endothelial Monolayers
To explore whether MASP-1 has any effect on the barrier
function of endothelial monolayers, we conducted real-time
impedance measurements using the xCELLigence system.
Treating HUVECs with 2µM rMASP-1 resulted in a sharp
decline of impedance with a minimum at 15–20min after
treatment and an overall duration of approximately 1 h, around
which impedance has stabilized at a level slightly under
baseline (Figure 1). This effect of rMASP-1 was similar to the
response triggered by the well-known permeability increasing
agonist thrombin.
rMASP-1 Significantly and
Dose-Dependently Increases
Endothelial Permeability
Although results with the xCELLigence system postulated that
MASP-1 can increase endothelial permeability, the findings
needed to be confirmed, as xCELLigence does not measure
true mass transport. Permeability tests were carried out
FIGURE 1 | rMASP-1 treatment reversibly decreases the impedance of the
endothelial monolayer. 96 well E-plate (Roche, Hungary) mounted by golden
microelectronic sensor arrays was pre-coated with 0.5% gelatin, and HUVECs
were seeded onto the surface and cultured for 3 days. Confluent HUVEC
monolayers were treated with 2µM rMASP-1 or 100 nM thrombin or the
culture medium only. Throughout the experiments, cells were kept in incubator
at 37◦C and monitored every 1min. Cell index for each time point was
determined using the following formula: (Rn—Rb)/15, where Rn is the
cell-electrode impedance of the well when it contains cells and Rb is the
background impedance of the well with the medium alone. Values of cell index
are therefore dimensionless and are directly proportional to the electrical
permeability of the cell layer. Cell indices of MASP-1 and thrombin treated cells
were normalized with that of the control (cells treated with growth medium
only). Representative of three independent experiments. The arrow indicates
the addition of treatment.
using a modified version of the recently developed XPerT
technique, which is a simple, high-throughput and cost-effective
assay for the measurement of true mass transport through
endothelial monolayers.
rMASP-1 induced an approximately 5-fold increase in the
permeability of HUVEC monolayers, and thrombin, used as
positive control, triggered a comparable permeability change
(Figure 2). rMASP-1 elicited permeability was dose dependent
and was completely inhibited by C1-INH and also by SGMI-1.
rMASP-1 Induced Endothelial Permeability
Is Dependent on PAR-1 and
ROCK Activation
We previously reported that rMASP-1 can cleave PAR-1, PAR-
2, and PAR-4. Since PAR-dependent cell activation accompanied
by intracellular Ca2+ mobilization is an important step in
permeability induction, we investigated the role of various PARs
in the rMASP-1 triggered Ca2+ response in HUVECs using PAR-
agonists and -antagonists. Treating the cells with PAR-1 agonist
induced a strong increase of intracellular [Ca2+], while the PAR-
4 agonist only had a mild effect. The PAR-2 agonist failed to
elicit any response (Figures 3A,B). In accordance with these
results, rMASP-1 triggered Ca2+ mobilization was significantly
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FIGURE 2 | rMASP-1 treatment increases endothelial permeability. Confluent layers of HUVECs were seeded onto 96 well plates pre-coated with biotinylated gelatin
and were treated with various concentrations of rMASP-1 or a mixture of rMASP-1 and its inhibitors SGMI-1 or C1-inhibitor together or with the culture medium alone
(control) for 20min. Streptavidin-Alexa488 was added to each well, and after cell fixation, pictures were taken using an Olympus IX-81 fluorescence microscope and
an Olympus XM-10 camera with 10x magnification Olympus lenses (numerical aperture: 0.3). (A) Representative images of three independent experiments. The scale
bar applies to all photomicrographs. (B) Size of the stained area was determined on each image using the CellP software. Mean values of three independent
experiments normalized to the controls are shown. ***p < 0.005, compared to the control, analyzed by one-way ANOVA and post-test for linear trend; ns,
non-significant; ###p < 0.005, compared to the 2µM rMASP-1 treated.
blocked by PAR-1 antagonist pretreatment, while PAR-2 and
PAR-4 antagonists showed no significant effect (Figures 3C,D).
Next, we investigated the PAR-dependence of the permeability
increasing effect of rMASP-1. Similarly to rMASP-1, the
PAR-1, and PAR-4 agonists significantly increased endothelial
permeability, while the PAR-2 agonist did not (Figure 4A).
Pretreating HUVECs with PAR-1 antagonist strongly blocked
the rMASP-1 triggered permeability change, while antagonists
of PAR-2 and PAR-4 were ineffective in the prevention of the
rMASP-1 elicited permeability response (Figure 4B).
Then, we examined the role of MLCK and ROCK (two
protein kinases important in cytoskeletal remodeling) in the
permeability increasing effect of rMASP-1. ROCK inhibitor Y-
27632 completely prevented the rMASP-1 induced permeability,
and what is more, the intensity of paracellular transport through
Y-27632 pretreated monolayers was even lower than that of the
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FIGURE 3 | PAR-1 mediates the rMASP-1 triggered intracellular Ca2+ mobilization in HUVECs. Confluent layers of HUVECs were seeded onto 96 well plates and
cultured for 1 day. Cells were loaded with Fluo-4 AM. (A,B) Sequential images were obtained every 5 s by fluorescence microscopy using an Olympus IX-81
fluorescence microscope and an Olympus XM-10 camera with 20x magnification Olympus lenses (numerical aperture: 0.45). Three photos were taken to determine
the baseline fluorescence, then cells were treated with 2µM rMASP-1 or PAR-agonists (4µM PAR-1 agonist, 0.4µM PAR-2 agonist or 1mM PAR-4 agonist) or the
culture medium only (control). (C,D) Cells were pretreated with or without PAR antagonists (0.68µM PAR-1 antagonist; 20µM PAR-2 antagonist or 0.28µM PAR-4
antagonist) for 10min. Sequential images were obtained every 5 s by fluorescence microscopy. Three photos were taken to determine the baseline fluorescence, then
cells were treated with rMASP-1 or with culture medium alone (control) and the response was measured for 2min. Images were then analyzed using the CellP
software. (A,C) data from a single, representative experiment, where fluorescence intensity values were background corrected and normalized to the control. (B)
Means of the maximum fluorescence intensity values normalized to that of the control are presented. Data from three independent experiments. (D) Means of the
maximum fluorescence intensity values are expressed as the percentage of rMASP-1 treatment (control: 0%). Data from three independent experiments. ***p < 0.005,
compared to the control; ###p < 0.005 compared to the rMASP-1 treated; ns, non-significant.
control. MLCK inhibitor, on the other hand, failed to prevent the
effect of rMASP-1 (Figure 4B).
rMASP-1 Induces MLC Phosphorylation
and Rearrangement of the Actin
Cytoskeleton in a PAR-1 and ROCK
Dependent Manner
We investigated the cytoskeletal changes underlying rMASP-1
induced endothelial permeability. Similarly to thrombin, rMASP-
1 induced a strong MLC di-phosphorylation and rearrangement
of the actin cytoskeleton of HUVECs resulting in stress fiber
formation, moreover, di-phosphorylated MLC and rearranged
actin fibers strongly co-localized (Pearson’s R = 0.48). These
effects of rMASP-1 were completely blocked by C1-INH
(Figure 5) and SGMI-1 (data not shown). Pretreating the cells
with PAR-1 antagonist also reduced the extent of MLC di-
phosphorylation and stress fiber formation triggered by rMASP-
1, while the PAR-2 and PAR-4 antagonists were ineffective.
The ROCK inhibitor Y-27632 completely prevented the rMASP-
1 induced cytoskeletal changes, moreover, this pretreatment
resulted in a total absence of di-phosphorylated MLC and actin
stress fibers (Figure 5). On the contrary, MLCK inhibitor ML-7
failed to avert the effect of rMASP-1.
rMASP-1 Changes the Pattern of
Molecules Important in Endothelial
Cell Adhesion
We also examined the rMASP-1 induced changes in the pattern
of some important EC adhesion molecules. In these experiments,
the untreated controls showed a well-organized, uninterrupted
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FIGURE 4 | PAR-1 and ROCK plays a key role in the rMASP-1 induced endothelial permeability. Confluent layers of HUVECs were seeded onto 96 well plates
pre-coated with biotinylated gelatin and were cultured for 2 days. Following cell treatment, streptavidin-Alexa488 was added to each well and after cell fixation,
pictures were taken using fluorescence microscopy using an Olympus IX-81 fluorescence microscope and an Olympus XM-10 camera with 10x magnification
Olympus lenses (numerical aperture: 0.3). Size of the stained area was determined on each image using the CellP software in three independent experiments. (A)
Cells were treated with 2µM rMASP-1 or PAR-agonists (4µM PAR-1 agonist, 0.4µM PAR-2 agonist or 1mM PAR-4 agonist) or the culture medium alone for 20min.
Values are expressed as fold-change relative to the control. (B) Cells were pretreated with or without PAR antagonists (0.68µM PAR-1 antagonist; 20µM PAR-2
antagonist or 0.28µM PAR-4 antagonist) for 10min then were treated with 2µM rMASP-1 for 20min. Values are expressed as the percentage of rMASP-1 treatment
(0% = cells treated only with the culture medium). ***p < 0.005, compared to the control; ###p < 0.005, compared to rMASP-1 treated; ns, non-significant.
network of adhesion molecules VE-cadherin and PECAM-
1, and intracellular adaptor molecule ZO-1, while rMASP-1
treatment resulted in a prominent disruption of this pattern and
induced paracellular gap formation. This effect of rMASP-1 was
completely blocked by C1-INH (Figure 6).
rMASP-1 Significantly Changes the
Expression of Several Permeability Related
Genes and May Facilitate the Effect
of Bradykinin
Finally, we performed whole transcriptome microarray analysis
to investigate whether rMASP-1 influences the expression of
permeability related genes in HUVECs as a prolonged effect.
Treating the cells with rMASP-1 for 2 h eventuated in significant
changes in the expression levels of 25 permeability related
genes. For 12 out of these genes (9 up-regulated and 3
down-regulated) we found direct experimental evidence in the
current literature verifying their role in regulating endothelial
permeability (Table 1). For example, rMASP-1 up-regulated the
expression of bradykinin B2 receptor (B2R) that is the endothelial
cell surface receptor for the well-known edematogenic factor
bradykinin. Furthermore, among the MASP-1 regulated genes,
we identified an additional set of 6 genes (3 up-regulated and
3 down-regulated) with indirect experimental evidence—namely
evidence for their role in modulating the effects of known
regulators of the barrier properties of the endothelium, and also
found a set of 7 genes (4 up-regulated and 3 down-regulated)
that are suspected to affect endothelial permeability, but lack
experimental evidence on their permeability-related role in EC
systems (Supplemental Table 1). We also tested the effects of
various known permeability increasing agonists such as LPS,
histamine, thrombin and TNF-α on the gene expression of
HUVECs, and found that expression of 68% (17 genes) of
the permeability related genes regulated by rMASP-1 was also
modulated by one or more of these mediators, while 8 genes
were found to be regulated exclusively by rMASP-1 (Table 1
and Supplemental Table 1). Interestingly, with only one single
exception, genes regulated both by rMASP-1 as well as by
any of the above mentioned permeability increasing agonists
manifested expression level alteration in the same direction
regardless of the agonist applied. Furthermore, expression of 4
rMASP-1 regulated genes were also regulated by all of the above
mentioned agonists.
DISCUSSION
Here we report the first case when the permeability
increasing function of a complement serine protease is
demonstrated. We provided evidence that MASP-1, a key
serine protease of complement lectin pathway, induces
endothelial hyperpermeability in a PAR-1 and ROCK
dependent manner. Using whole-transcriptome analysis,
we also showed that MASP-1 may have a prolonged effect on
endothelial paracellular transport, as rMASP-1 treatment
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FIGURE 5 | rMASP-1 treatment reorganizes the actin cytoskeleton of endothelial cells. Confluent layers of HUVECs were seeded onto 18 well ibidiTM slides and were
cultured for 2 days. Cells were pretreated with or without PAR antagonists (0.68µM PAR-1 antagonist; 20µM PAR-2 antagonist or 0.28µM PAR-4 antagonist) for
10min or 2.5µM ROCK inhibitor (Y-27632) for 15min, then were treated with 2µM rMASP-1 or 300 nM thrombin for 20min. Cells treated with culture medium only
served as a negative control. After fixation, cells were stained with anti-pMLC antibody. F-actin cytoskeleton was stained with phalloidin-Alexa488, cell nuclei were
labeled with Hoechst 33258 and pictures were taken using an Olympus IX-81 fluorescence microscope and an Olympus XM-10 camera with 40x magnification
Olympus lenses (numerical aperture: 0.75). Representative images from three independent experiments are shown. The scale bar applies to all photomicrographs.
significantly affected the expression level of numerous
permeability-related genes.
In vivo, MASP-1 binds to PRMs, but purification of these
complexes are still quite challenging, moreover, the distribution
of MASP-1 amongst the various PRMs remains largely unknown.
In the current study, a recombinant catalytic fragment of
MASP-1 (rMASP-1) was used, which contains only the three
C-terminal domains of the native protein, therefore cannot
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FIGURE 6 | rMASP-1 treatment changes the pattern of endothelial cell adhesion molecules. Confluent layers of HUVECs were seeded onto 18 well ibidiTM slides and
cultured for 2 days. Cells were either treated with 300 nM thrombin, 2µM rMASP-1, a mixture of rMASP-1 and C1-inhibitor or with the culture medium alone (control)
for 20min. After fixation, cells were stained with anti-VE-cadherin, anti-ZO-1, or anti PECAM-1 antibodies (green). Cell nuclei were labeled with Hoechst 33258 (blue)
and images were taken using an Olympus IX-81 fluorescence microscope and an Olympus XM-10 camera with 40x magnification Olympus lenses (numerical
aperture: 0.75). Representative images from three independent experiments are shown. The scale bar applies to all photomicrographs. In the case of adhesion
molecule VE-cadherin and intracellular adaptor ZO-1, the untreated control shows a well-organized, uninterrupted network of junctional molecules in the cell-cell
junction areas, while rMASP-1 treatment (similarly to the positive control thrombin) resulted in a prominent disruption of this pattern (white arrows) indicating
paracellular gap formation. This effect of rMASP-1 was completely blocked by C1-INH. A clear visualization of paracellular gaps can be seen in the case of adhesion
molecule PECAM-1 as it is distributed evenly throughout the cell surface. Untreated cells form a continuous layer, while in response to rMASP-1 treatment, cells
moved apart from each other to form paracellular gaps (white arrows), which was completely inhibited by C1-INH.
dimerize or bind to pattern recognition molecules, but preserves
enzymatic activity. This choice is justified by our earlier results,
strongly suggesting that the catalytic fragment is necessary and
sufficient for the cellular effects of the native MASP-1. First,
the N-terminal fragment and the zymogen mutant forms of
MASP-1 lacking enzymatic activity failed to induce intracellular
Ca2+ mobilization in HUVECs, while the recombinant, catalytic
fragment triggered a similar response as the native, MBL-
complexed form (13). Furthermore, as we show in the current
paper, C1-INH and the highly specific small molecule MASP-1
inhibitor SGMI-1 could completely prevent all the tested cellular
effects of MASP-1.Taken together, although minor differences
in their effects might occur between the recombinant, catalytic
fragment of MASP-1 and the physiological MASP-1 complexes,
the utilization of rMASP-1 may be a good model of most
in vivo situations.
One of the main physiological roles of ECs is to form
a tightly regulated barrier between the lumen of vessels
and the interstitial space. This is achieved by a resting
phenotype—generally characterized by well-oganized cell-cell
junctions. However, various factors are able to transform
this state into a leaky or hyperpermeable phenotype, when
endothelial cell-cell junctions are disrupted and the endothelium
becomes rich in paracellular gaps, facilitating paracellular
transport. The xCELLigence system is an ideal platform for
real-time screening of potential permeability increasing agents
(47). With this system, we observed that, similarly to the
well-known permeability increasing agonist thrombin, rMASP-
1 induced a prominent decrease in the impedance of the
HUVEC monolayer, strongly suggesting that rMASP-1 is able
to increase endothelial permeability at least regarding the ion-
current. To confirm this effect at the level of macromolecular
transport, we utilized the XPerT permeability assay (28).
XPerT is able to measure macromolecular transport similarly
to TranswellTM, however, the statistical reliablity of XPerT
is superior due to its high-throughput testing capacity (28).
In the XPerT system, rMASP-1 significantly increased the
intensity of paracellular transport that could be blocked
by C1-inhibitor as well as the highly specific MASP-1
inhibitor, SGMI-1.
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Along the multistep, permeability increasing agonist
mediated transition between the resting and the hyperpermeable
phenotype of ECs the first step is their receptor-mediated
activation, which is usually accompanied by a transient increase
of intracellular [Ca2+] (22). For example, thrombin induced
EC activation starts with a Ca2+ response initiated by the
cleavage of EC surface PAR-1 (48). In our previous work,
we have provided evidence that rMASP-1 elicits intracellular
Ca2+ mobilization and thereby activates ECs (12, 13). We
supposed that this activation is PAR-mediated, as we found
that the catalytically inactive form of MASP-1 was unable
to initiate any cellular response (13). Additionally, we have
also shown earlier that rMASP-1 is indeed able to cleave
PAR-1, PAR-2 and PAR-4 mimicking synthetic substrates—
most efficiently the PAR-4 peptide, and PAR-4 was found to
be important in MASP-1 triggered inflammatory response
in HUVECs (12). In the current study, we investigated
the PAR-dependence of rMASP-1 triggered EC activation
and identified PAR-1 as the main mediator of this process
as only the PAR-1 antagonist pretreatment could prevent
the effects of rMASP-1. Nevertheless, PAR-1 antagonist
could not completely block the permeability increasing and
the Ca2+ mobilizing effects of rMASP-1, therefore, to a
lesser extent, these may also be influenced by signaling via
PAR-4, PAR heterodimers or other biased PAR signaling
(49). A similar contribution of PAR-1 to the permeability
increasing effect of thrombin is well-established in the
literature (50–53). The differential contribution of PAR-1
and PAR-4 to the permeability and inflammatory response,
respectively, shows that MASP-1 may regulate EC phenotype in
a complex way.
Cytoskeletal rearrangement is an important prerequisite
for paracellular gap formation. In their basal, quiescent state
ECs show a cortical, ring-like organization of cytoskeletal
F-actin. Permeability increasing agonists, such as thrombin,
reorganize this structure into fiber-like bundles, called stress
fibers, spreading throughout the cytoplasm. This transformation
requires a Thr-18/Ser-19 diphosphorylated state of MLC
established by phosphorylation and dephosphorylation events.
Phosphorylation ofMLC is catalyzed byMLCK and ROCK, while
dephosporylation is mediated by MLC phosphatase (MLCP)
(54). As ROCK can directly phosphorylate MLC, and also
inactivate MLCP, it is considered a key regulator of cytoskeletal
changes (55, 56). ROCK was found to mediate the endothelial
barrier disrupting effect of thrombin as its selective inhibitor
(Y-27632) prevented thrombin-induced MLC phosphorylation,
stress fiber formation, and hyperpermeability in ECs (53).
In our experiments, similarly to thrombin, rMASP-1 induced
MLC diphosphorylation, and stress fiber formation. Pretreating
ECs with Y-27632 blocked these effects, and also prevented
rMASP-1 triggered endothelial hyperpermeability, while MLCK
inhibitor ML-7 failed to prevent these events. Taken together, our
results clearly show the key importance of ROCK in rMASP-1
elicited cytoskeletal changes and endothelial hyperpermeability,
whereas the role of MLCK in this process needs to be
further investigated.
Paracellular gap formation also requires the disruption of
endothelial cell-cell junctions. To investigate the effects of
rMASP-1 on these structures, we visualized three key molecules
involved in the interconnection of ECs. Similarly to thrombin,
rMASP-1 changed the pattern of molecules involved in EC-
EC adhesion—it markedly disintegrated the network of VE-
cadherin [which is a well-known indicator of endothelial
hyperpermeability (57)], and also induced the disappearance of
the tight junction component ZO-1 from the junctional areas.
Furthermore, with the staining of PECAM-1 we provide evidence
that—like thrombin—rMASP-1 increases the number and size of
paracellular gaps, which is in line with the observed increase in
paracellular permeability.
We have recently reported that in ECs, rMASP-1 regulates
the expression of genes involved in the inflammatory reaction
(29). Here we show that rMASP-1 treatment significantly
changed the expression of 25 permeability-related genes. The
majority of rMASP-1 regulated genes were also regulated by
one or more of the four well-known permeability increasing
agonists, LPS, histamine, thrombin and TNF-α. These agonists
modulated EC gene expression in the same direction as
rMASP-1. One of the most interesting findings of our
transcriptome analysis was that rMASP-1 treatment significantly
up-regulated the expression of bradykinin receptor B2R, which
mediates the edematogenic effect of bradykinin. Bradykinin—
proteolytically produced mainly by kallikrein—is known as the
key edematogenic factor in the pathomechanism of HAE (39).
However, we have recently shown that MASP-1 can also produce
bradykinin by cleaving high-molecular-weight kininogen (11).
Regardless of the source of bradykinin, up-regulation of B2R
by MASP-1 can be important in the senzitization of ECs
toward hyperpermeability.
Recently, the group of Wang et al., showed that a complement
activation fragment, C4a serves as an untethered ligand for PAR-
1 and PAR-4, and activates these receptors in a non-proteolytic
manner (58). It is noteable that MASP-1 also contributes to
the generation of C4a via MASP-2 activation. C4a mediated
activation of PAR-1 also resulted in stress fiber formation, and
increased endothelial permeability (58). These results underline
the importance of our findings, and raise the possibility that
components of the complement systemmay also affect the barrier
function of the vessel wall.
According to our results, MASP-1 may play a role in several
diseases, where edema formation is preceded by lectin pathway
activation. One such condition can develop in patients with
HAE, a life-threatening disease caused by the deficiency of C1-
INH, the natural inhibitor of MASP-1, where MASP-1—due
to its permeability increasing effect—may act as a potential
triggering factor of edematous attacks. This is supported by the
observation that infections can trigger HAE attacks (59) and by
the recent finding that the levels of MASP-1 and MASP-1/C1-
INH complexes are linked to disease severity in HAE patients
(60). Furthermore, it is plausible that the permeability increasing
effect of MASP-1 can contribute to the edema formation in
septic or ischemia/reperfusion injury patients. In the future, in
vivo experiments are needed to investigate the role of MASP-
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1 in the pathomechanism of the above mentioned diseases.
If MASP-1 proves to be an indeed important player in HAE,
sepsis, and ischemia/reperfusion, it can be a promising target for
drug development.
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